A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients

[1]  Michèle Rouleau,et al.  Pharmacogenomics of Human Uridine Diphospho‐Glucuronosyltransferases and Clinical Implications , 2014, Clinical pharmacology and therapeutics.

[2]  Soma Das,et al.  Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Hartman,et al.  The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: Haplotype associations and gene–environment interactions , 2014, Genes, chromosomes & cancer.

[4]  W. V. van IJcken,et al.  HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers. , 2014, The Journal of clinical investigation.

[5]  Julia M. Barbarino,et al.  PharmGKB summary: very important pharmacogene information for UGT1A1 , 2014, Pharmacogenetics and genomics.

[6]  V. Zagonel,et al.  Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment , 2013, Pharmacogenetics and genomics.

[7]  M. Baiget,et al.  Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan , 2013, The Pharmacogenomics Journal.

[8]  William M. Lee,et al.  The UDP-Glucuronosyltransferase (UGT) 1A Polymorphism c.2042C>G (rs8330) Is Associated with Increased Human Liver Acetaminophen Glucuronidation, Increased UGT1A Exon 5a/5b Splice Variant mRNA Ratio, and Decreased Risk of Unintentional Acetaminophen-Induced Acute Liver Failure , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[9]  K. Mohlke,et al.  Allele-Specific Transcriptional Activity at Type 2 Diabetes–Associated Single Nucleotide Polymorphisms in Regions of Pancreatic Islet Open Chromatin at the JAZF1 Locus , 2013, Diabetes.

[10]  C. Guillemette,et al.  Refining the UGT1A Haplotype Associated with Irinotecan-Induced Hematological Toxicity in Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Irinotecan-Based Regimens , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[11]  R. Mckinnon,et al.  Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. , 2012, Pharmacogenomics.

[12]  M. Baiget,et al.  A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer , 2011, British Journal of Cancer.

[13]  Q. Pei,et al.  Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk , 2010, Clinical Cancer Research.

[14]  Zhe-yi Hu,et al.  Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. , 2010, European journal of cancer.

[15]  F. Innocenti,et al.  Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Ming-Huei Chen,et al.  Genome-wide association meta-analysis for total serum bilirubin levels. , 2009, Human molecular genetics.

[17]  Federico Innocenti,et al.  Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[19]  C. Guillemette,et al.  The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[20]  J. Verweij,et al.  Hepatic transport, Metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain , 2006, Cancer biology & therapy.

[21]  Giuseppe Toffoli,et al.  The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Guillemette,et al.  THE NOVEL UGT1A9 INTRONIC I399 POLYMORPHISM APPEARS AS A PREDICTOR OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDATION LEVELS IN THE LIVER , 2006, Drug Metabolism and Disposition.

[23]  Alex Sparreboom,et al.  Pharmacogenetics of irinotecan metabolism and transport: an update. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[24]  C. Guillemette,et al.  UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver , 2005, Hepatology.

[25]  M. Ratain,et al.  Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes , 2005, Pharmacogenetics and genomics.

[26]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[27]  C. Guillemette,et al.  Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.

[28]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[29]  E. Beutler,et al.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Marsh,et al.  Irinotecan pharmacogenomics. , 2010, Pharmacogenomics.